Production (Stage)
Cardiff Oncology, Inc.
CRDF
$3.86
$0.051.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.43M | -11.79M | -11.86M | -11.78M | -10.01M |
| Total Depreciation and Amortization | 228.00K | 96.00K | 101.00K | 105.00K | 236.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.23M | 1.05M | 1.10M | 1.05M | 968.00K |
| Change in Net Operating Assets | -816.00K | 378.00K | 202.00K | 1.39M | 1.07M |
| Cash from Operations | -12.79M | -10.27M | -10.46M | -9.23M | -7.74M |
| Capital Expenditure | -- | 0.00 | 0.00 | 0.00 | -80.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -14.58M | 4.51M | -9.43M | 14.02M | 4.72M |
| Cash from Investing | -14.58M | 4.51M | -9.43M | 14.02M | 4.64M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.00K | 44.19M | 7.43M | 2.06M | 107.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3.00K | 44.19M | 7.43M | 2.06M | 107.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -27.38M | 38.43M | -12.46M | 6.84M | -3.00M |